Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: Application of epidemiological cutoff values to results from a global candida antifungal surveillance program

Journal of Clinical Microbiology

Volumn 49, Issue 4, 2011, Pages 1274-1279

  Pfaller, M A ^a,b   Boyken, L B ^a   Hollis, R J ^a   Kroeger, J ^a   Messer, S A ^a   Tendolkar, S ^a   Diekema, D J ^a,c  

^a Medical Microbiology Division   (United States)

^b Division of Epidemiology Human Genetics Environmental Sciences   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA METAPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDA ZEYLANOIDES; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FUNGAL STRAIN; FUNGUS ISOLATION; INCUBATION TIME; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; YARROWIA LIPOLYTICA;

ANTIFUNGAL AGENTS; CANDIDA; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TIME FACTORS; TRIAZOLES;

CANDIDA; CANDIDA PARAPSILOSIS;

EID: 79953883547     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02437-10     Document Type: Article

References (39)

1. Arendrup, M. C., and D. W. Denning. 2007. Does one voriconazole breakpoint suit all Candida species? J. Clin. Microbiol. 45:2093-2094.
2. Arnold, H. M., et al. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361-368.
3. Arthington-Skaggs, B. A., et al. 2002. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob. Agents Chemother. 46:2477-2481. (Pubitemid 34793452)
4. Baddley, J. W., et al. 2004. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn. Microbiol. Infect. Dis. 50:119-124. (Pubitemid 39335847)
5. Baddley, J. W., M. Patel, S. M. Bhavnani, S. A. Moser, and D. R. Andes. 2008. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 52:3022-3028.
6. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd informational supplement. M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Collins, C. D., G. A. Eschenauer, S. L. Salo, and D. W. Newton. 2007. To test or not to test: A cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J. Clin. Microbiol. 45: 1884-1888. (Pubitemid 46933921)
9. Espinel-Ingroff, A., et al. 2005. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: A collaborative study. J. Clin. Microbiol. 43:4535-4540. (Pubitemid 41298239)
10. Espinel-Ingroff, A., et al. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43:3884-3889. (Pubitemid 41129676)
11. Espinel-Ingroff, A., E. Canton, J. Peman, M. G. Rinaldi, and A. W. Fothergill.2009. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: Results obtained with 2,162 clinical isolates of Candida spp. and other yeasts. J. Clin. Microbiol.47:2766-2771.
12. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). 2008. EUCAST technical note on voriconazole. Clin. Microbiol. Infect. 14:985-987.
13. Forrest, G. 2006. Role of antifungal susceptibility testing in patient management. Curr. Opin. Infect. Dis. 19:538-543. (Pubitemid 44665459)
14. Garey, K. W., et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin. Infect. Dis. 43:25-31. (Pubitemid 43939072)
15. Garey, K. W., R. S. Turpin, D. T. Bearden, M. P. Pai, and K. J. Suda. 2007. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidemia: A multi-institutional study. Int. J. Antimicrob. Agents 29:557-562. (Pubitemid 46560362)
16. Hadley, S., J. A. Martinez, L. McDermott, B. Rapino, and D. R. Snydman. 2002. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J. Antimicrob. Chemother. 49:415-419. (Pubitemid 34162641)
17. Hazen, K. C., and S. A. Howell. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p. 1762-1788. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
18. Hospenthal, D. R., C. K. Murray, and M. G. Rinaldi. 2004. The role of antifungal susceptibility in the therapy of candidiasis. Diagn. Microbiol. Infect. Dis. 48:153-160. (Pubitemid 38340513)
19. Hsu, D. I., M. Nguyen, L. Nguyen, A. Law, and A. Wong-Beringer. 2010. A multicenter study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J. Antimicrob. Chemother. 65:1765-1770.
20. Kahlmeter, G., et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148. (Pubitemid 36986868)
21. Kahlmeter, G., and D. F. J. Brown. 2004. Harmonization of antimicrobial breakpoints in Europe-can it be achieved? Clin. Microbiol. Newsl. 26:187-192. (Pubitemid 40142649)
22. Labelle, A. J., S. T. Micek, N. Roubinian, and M. H. Kollef. 2008. Treatmentrelated risk factors for hospital mortality in Candida bloodstream infections. Crit. Care Med. 36:2967-2972.
23. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: Case-report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44:529-535. (Pubitemid 43222248)
24. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for mortality. Antimicrob. Agents Chemother. 49:3640-3645. (Pubitemid 41233011)
25. Ostrosky-Zeichner, L., et al. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154. (Pubitemid 37229571)
26. Ostrosky-Zeichner, L., et al. 2008. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob. Agents Chemother. 52:4175-4177.
27. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
28. Parkins, M. D., D. M. Sabuda, S. Elsayed, and K. B. Laupland. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618. (Pubitemid 47299877)
29. Pfaller, M. A., et al. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: Analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
30. Pfaller, M. A., et al. 2008. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: Results from a global Candida antifungal surveillance program. J. Clin. Microbiol. 46: 3585-3590.
31. Pfaller, M. A., et al. 2008. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: Results from a global antifungal surveillance program. J. Clin. Microbiol. 46:551-559. (Pubitemid 351231301)
32. Pfaller, M. A., et al. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updates 13:180-195.
33. Pfaller, M. A., et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-h CLSI broth microdilution. J. Clin. Microbiol. 49:630-637.
34. Pfaller, M. A., et al. 2011. Comparison of the broth microdilution (BMD) method of the European Committee on Antibacterial Susceptibility Testing (EUCAST) with the 24-h CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J. Clin. Microbiol. 49:845-850.
35. Revankar, S. G., et al. 1998. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J. Clin. Microbiol. 36:153-156. (Pubitemid 28047451)
36. Rex, J. H., et al. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134. (Pubitemid 28053338)
37. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989. (Pubitemid 35178316)
38. Sabatelli, F., et al. 2006. In vitro activity of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50: 2009-2015. (Pubitemid 43807519)
39. Zilberberg, et al. 2010. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: A retrospective cohort study. BMC Infect. Dis. 10:150-156.